Clinical Trial Update: Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients [Phase 2]

View source ↗

Summary

A phase 2 trial investigating induction of hypothyroxinemia as an adjunct to standard therapies in glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Induction of hypothyroxinemia adjunct therapy

Snippet

Sponsor: Musli Thyropeutics Ltd. | Conditions: Glioblastoma Multiforme (GBM) | Phase 2 | Status: TERMINATED